A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.
Strayer, David R, Carter, William A, Stouch, Bruce C et al.·PloS one·2012
This study tested whether a drug called rintatolimod (a molecule designed to activate immune responses) could help people with severe ME/CFS. Over 230 patients received either the drug or a placebo twice a week for 40 weeks. Patients who received rintatolimod improved their exercise tolerance by about 21%, and they also needed fewer medications to manage their symptoms.